Targeted therapy: RAS mimetic revealed

Nature Reviews Cancer 16, 342 (2016). doi:10.1038/nrc.2016.59 Author: Alexandra Flemming The small-molecule inhibitor rigosertib acts as a RAS mimetic — by disrupting the association of RAS with RAF and other effector proteins, it inactivates RAS downstream signalling.
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Research Highlight Source Type: research